Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1007/s00262-014-1647-3.pdf
Reference11 articles.
1. Weber J, Minor D, D’Angelo S, Hodi FS, Gutzmer R, Neyns B et al (2014) A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. ESMO Abstract LBA3_PR
2. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
3. McDermott D, Kluger H, Sznol M, Carvajal R, Lawrence D, Topalian SL et al (2014) Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in a phase 1 trial. ESMO Abstract 1088PD
4. Robert C, Joshua A, Weber J, Ribas A, Hodi FS, Kefford R et al (2014) Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): Randomized comparison of two dosing schedules. ESMO Abstract LBA34
5. Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD et al (2014) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 32(5s):LBA9000
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Study of epirubicin sustained–release chemoablation in tumor suppression and tumor microenvironment remodeling;Frontiers in Immunology;2022-12-20
2. Research progress on anti-tumor immune effect of cryoablation;Chinese Journal of Academic Radiology;2022-03-18
3. Correlation between Autophagy and Drug Resistance of Melanoma BRAF Inhibitors;Advances in Clinical Medicine;2022
4. A structural perspective on the design of decoy immune modulators;Pharmacological Research;2021-08
5. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer;Cancer Cell International;2020-08-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3